Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05789056 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome

StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Dec 30, 2025 → Dec 30, 2026
See other at-risk trials from Quoin Pharmaceuticals

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Dec 30, 2025 to Dec 30, 2026v6
  2. Primary and study completion dates: Dec 30, 2024 to Dec 30, 2025v5
  3. Enrollment target: 10 to 20
    • Study sites: 2 to 4
    • Eligibility criteria revised
    • Study arms: 1 to 2
    v4
  4. Primary completion date: Jul 30, 2023 to Dec 30, 2024
    • Study completion date: Dec 24, 2023 to Dec 30, 2024
    v3
  5. Primary endpoints revised (8)v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To assess the safety, tolerability, and efficacy of QRX003 lotion (4%) when added to standard of care treatment regimen, including systemic therapy in subjects with Netherton syndrome
Trial Details
NCT Number NCT05789056
Lead Sponsor Quoin Pharmaceuticals
Conditions
(from sponsor)		 Netherton Syndrome
Related terms Netherton Syndrome
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov